Lindsetmo R O, Revhaug A
Kirurgisk avdeling Regionsykehuset i Tromsø.
Tidsskr Nor Laegeforen. 1994 Oct 10;114(24):2829-30.
Hypersecretory stomas or fistulas are disabling conditions for the patients and a therapeutic challenge to the surgeons. Octreotide treatment is reported to reduce stoma output and the need for intravenous supplements. Octreotide treatment also reduces social disability due to postprandial hypersecretion causing frequent changes of stoma systems. Two patients with high output stomas and one patient with high output ileocutaneous fistula were treated with the somatostatin analogue octreotide. Reductions in stoma or fistula output from 48 to 62% were observed.
高分泌性造口或瘘管对患者来说是致残性病症，对外科医生而言是一项治疗挑战。据报道，奥曲肽治疗可减少造口排出量以及静脉补充营养的需求。奥曲肽治疗还可减少因餐后高分泌导致造口装置频繁更换所引起的社交障碍。对两名高排出量造口患者和一名高排出量回肠皮肤瘘患者使用生长抑素类似物奥曲肽进行治疗。观察到造口或瘘管排出量减少了48%至62%。
